China Universal Asset Management Co., Ltd. Viracta Therapeutics, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Oct 21, 2022	BUY	$3.32 - $5.69 $1,168 - $2,002	352 New	352 $2,000

Others Institutions Holding VIRX

# of Institutions

Shares Held

5.63M

Call Options Held

Put Options Held

Ken Griffin Citadel Advisors LLC | Chicago, Il

1.52M
Shares

$380,060
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

954K
Shares

$238,621
0.0% of portfolio
Samsara Bio Capital, LLC Palo Alto, CA

690K
Shares

$172,427
0.09% of portfolio
Stonepine Capital Management, LLC Bend, OR

500K
Shares

$125,000
0.07% of portfolio
Laurion Capital Management LP New York, NY

332K
Shares

$83,047
0.0% of portfolio

View Full List

About Viracta Therapeutics, Inc.

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $9.39M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

More about VIRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account